Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Intangibles (2016 - 2025)

Amicus Therapeutics filings provide 13 years of Intangibles readings, the most recent being $13.9 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 19.18% to $13.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.9 million, a 19.18% decrease, with the full-year FY2025 number at $13.9 million, down 19.18% from a year prior.
  • Intangibles hit $13.9 million in Q4 2025 for Amicus Therapeutics, down from $14.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $23.0 million in Q1 2021 to a low of $13.9 million in Q4 2025.
  • Median Intangibles over the past 5 years was $21.7 million (2023), compared with a mean of $20.3 million.
  • Biggest five-year swings in Intangibles: changed 0.0% in 2021 and later fell 19.18% in 2025.
  • Amicus Therapeutics' Intangibles stood at $23.0 million in 2021, then changed by 0.0% to $23.0 million in 2022, then decreased by 10.91% to $20.5 million in 2023, then dropped by 16.07% to $17.2 million in 2024, then fell by 19.18% to $13.9 million in 2025.
  • The last three reported values for Intangibles were $13.9 million (Q4 2025), $14.7 million (Q3 2025), and $15.6 million (Q2 2025) per Business Quant data.